Annexon (NASDAQ:ANNX) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Annexon (NASDAQ:ANNXFree Report) in a research note released on Wednesday morning, Benzinga reports.

Several other research analysts have also weighed in on the stock. Bank of America raised their price objective on shares of Annexon from $7.00 to $10.00 and gave the stock a buy rating in a report on Thursday, March 28th. Needham & Company LLC reissued a buy rating and set a $16.00 price objective on shares of Annexon in a report on Wednesday, March 27th. HC Wainwright reissued a buy rating and set a $30.00 price objective on shares of Annexon in a report on Wednesday, March 27th. Wells Fargo & Company raised their price objective on shares of Annexon from $11.00 to $12.00 and gave the stock an overweight rating in a report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Annexon from $11.00 to $13.00 and gave the stock an overweight rating in a report on Monday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon currently has an average rating of Buy and an average price target of $14.43.

Get Our Latest Analysis on ANNX

Annexon Trading Up 0.5 %

ANNX opened at $6.45 on Wednesday. The company has a fifty day simple moving average of $5.52 and a 200 day simple moving average of $3.81. The firm has a market cap of $343.40 million, a price-to-earnings ratio of -3.62 and a beta of 1.14. Annexon has a twelve month low of $1.57 and a twelve month high of $8.40.

Insider Transactions at Annexon

In other news, CEO Douglas Love sold 5,782 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $5.54, for a total value of $32,032.28. Following the transaction, the chief executive officer now directly owns 196,121 shares in the company, valued at approximately $1,086,510.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 8,940 shares of company stock worth $49,514. 19.11% of the stock is currently owned by insiders.

Institutional Trading of Annexon

Several hedge funds have recently bought and sold shares of ANNX. JPMorgan Chase & Co. lifted its position in Annexon by 23.9% in the 1st quarter. JPMorgan Chase & Co. now owns 91,090 shares of the company’s stock valued at $249,000 after purchasing an additional 17,550 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Annexon in the 1st quarter valued at about $388,000. Vanguard Group Inc. lifted its position in Annexon by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 1,095,032 shares of the company’s stock valued at $2,990,000 after purchasing an additional 19,722 shares during the last quarter. Federated Hermes Inc. lifted its position in Annexon by 50.7% in the 1st quarter. Federated Hermes Inc. now owns 3,052,651 shares of the company’s stock valued at $8,334,000 after purchasing an additional 1,027,051 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Annexon in the 1st quarter valued at about $100,000.

About Annexon

(Get Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.

Featured Stories

Analyst Recommendations for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.